155456-33-0

Usage

Uses

Used in Pharmaceutical Research:
N-BOC-4(benzyloxycarbonylaminomethyl)piperidine, 98% is used as a building block for the synthesis of various pharmaceutical drugs and bioactive molecules. Its BOC protecting group provides stability during the synthesis process, allowing for the creation of complex molecular structures with precise control over the reaction conditions.
Used in Organic Synthesis:
In the field of organic synthesis, N-BOC-4(benzyloxycarbonylaminomethyl)piperidine, 98% is utilized as a versatile intermediate for the preparation of a wide range of organic compounds. Its BOC protecting group can be selectively removed under mild conditions, enabling the synthesis of target molecules with high yields and purity.
Used in Drug Development:
N-BOC-4(benzyloxycarbonylaminomethyl)piperidine, 98% is employed in drug development as a key component in the design and synthesis of novel therapeutic agents. Its protective properties allow for the exploration of new chemical entities with potential medicinal applications, contributing to the advancement of pharmaceutical research and innovation.
Used in Bioactive Molecule Synthesis:
In the synthesis of bioactive molecules, N-BOC-4(benzyloxycarbonylaminomethyl)piperidine, 98% serves as a crucial intermediate. Its protective group ensures the integrity of the molecule during the synthesis process, facilitating the production of bioactive compounds with potential applications in medicine, agriculture, and other industries.
Used in High-Quality Applications:
Due to its 98% purity, N-BOC-4(benzyloxycarbonylaminomethyl)piperidine is suitable for use in high-quality applications where the purity of the starting material is critical for the success of the reaction or formulation. This makes it an ideal choice for sensitive applications in research and development, as well as in the production of high-purity pharmaceuticals and other specialty chemicals.

Upstream product

• 54244-69-8 tert-butoxycarbonylamino-acetic acid benzyl ester 
• 100-51-6 benzyl alcohol 
• 501-53-1 benzyl chloroformate 
• 144222-22-0 tert-butyl 4-(aminomethyl)piperidine-1-carboxylate 
• 584-08-7 potassium carbonate 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7144-05-0 4-Aminomethylpiperidine 

Downstream Products

• 155456-34-1 benzyl (piperidin-4-ylmethyl)carbamate hydrochloride 
• 132431-09-5 benzyl (piperidin-4-ylmethyl)carbamate 
• 1268465-02-6 tert-butyl 4-(((benzyloxycarbonyl)(propyl)amino)methyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Amide or sulfonamide substituted hydrazine derivative used as JAK kinase inhibitor

The invention provides an amide or sulfamide substituted hydrazine derivative. The derivative is characterized by being a compound as shown in the following structural formula which is described in the specification, and a stereoisomer, a geometrical isom

Anti-Markovnikov Radical Hydro- and Deuteroamidation of Unactivated Alkenes

Radical anti-Markovnikov hydro- and deuteroamidation of unactivated alkenes was achieved by merging photoredox and thiol catalysis. Reactions proceed by addition of the electrophilic CbzHN-radical (Cbz=carbobenzyloxy), readily generated by single-electron-transfer (SET) oxidation of an α-Cbz-amino-oxy acid to an alkene. The adduct radical is reduced by thiophenol added as an organic polarity reversal cocatalyst, which mediates the H transfer from H2O to the alkyl radical intermediate. Accordingly, deuteroamidation of alkenes was realized with excellent D incorporation by using D2O as the stoichiometric formal radical-reducing reagent. The reaction features low redox catalyst loading, excellent anti-Markovnikov selectivity, and the use of a large alkene excess is not required. Diverse Cbz-protected primary amines, including β-deuterated amines, can be obtained by applying this method.

SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS

The present invention relates to novel benzamide derivatives of formula (I) having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of diseases treatable by 5-HT4 agonism.

Integrin receptors antagonists

The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.

N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

Compounds represented by Formula (I): 1or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.